RPL7A

Across TCGA pan-cancer cohorts, RPL7A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RPL7A data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPL7A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL7A expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where RPL7A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.505	0.855	.001	25	view →
LUAD	DFS	Median	III,IV	0.783	0.269	.003	19	view →
HNSC	DFS	Median	III,IV	0.893	0.697	.008	14	view →
GBM	OS	Tertile	All	0.727	0.284	.002	10	view →
UCEC	OS	Median	II,III,IV	1.000	0.620	.011	8	view →
PDAC	DFS	Tertile	IV	0.182	0.515	.024	3	view →
LSCC	DFS	Tertile	III,IV	0.439	0.832	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPL7A–CCRCC (OS)

Open the CCRCC breakdown →